Sugi Predict

Sugi Predict / Compounds / SCHEMBL147477

SCHEMBL147477

SCHEMBL147477

Cc1ccc(-c2ccc(Cc3cc([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)ccc3C)s2)cc1

nearest known ligand 0.85

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ SLC5A2 P31639 20/20 0.85
▸ SLC5A1 P13866 3/20 0.85
▸ ABCB11 O95342 1/20 0.85
▸ ADORA3 P0DMS8 1/20 0.85
▸ SLC6A4 P31645 1/20 0.85
▸ SLC6A3 Q01959 1/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17034652 1.00 SLC5A2 (0.85) SLC5A2SLC5A1ABCB11ADORA3SLC6A4
SCHEMBL15887584 1.00 SLC5A2 (0.85) SLC5A2SLC5A1ABCB11ADORA3SLC6A4
SCHEMBL10062752 1.00 SLC5A2 (0.85) SLC5A2SLC5A1ABCB11ADORA3SLC6A4
SCHEMBL23135183 0.93 SLC5A2 (0.84) SLC5A2SLC5A1ABCB11ADORA3SLC6A4
SCHEMBL17294095 0.93 SLC5A2 (0.83) SLC5A2SLC5A1ABCB11ADORA3SLC6A4
SCHEMBL28404062 0.93 SLC5A2 (0.83) SLC5A2SLC5A1ABCB11ADORA3SLC6A4
Canagliflozin Anhydrous SCHEMBL16421559 0.92 SLC5A2 (1.00) SLC5A2SLC5A1ABCB11ADORA3SLC6A4
Canagliflozin Anhydrous SCHEMBL16075101 0.92 SLC5A2 (1.00) SLC5A2SLC5A1ABCB11ADORA3SLC6A4
Canagliflozin Anhydrous SCHEMBL19493514 0.92 SLC5A2 (1.00) SLC5A2SLC5A1ABCB11ADORA3SLC6A4
Canagliflozin Anhydrous SCHEMBL873848 0.92 SLC5A2 (1.00) SLC5A2SLC5A1ABCB11ADORA3SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230372375-A1 SGLT-2 INHIBITOR SARCOSINE CO-CRYSTAL, PREPARATION METHOD THEREFOR AND USE THEREOF OMNISINO HEALTH (TIANJIN) MEDICAL TECHNOLOGY CO. LTD (CN) 2023-11-23 — — US disclosed
US-11759474-B2 Use of SGLT-2 inhibitors in the drying-off of non-human mammals BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2023-09-19 — — US disclosed
US-20230140631-A1 TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2023-05-04 — — US disclosed
US-20180155329-A1 ANHYDROUS CRYSTALLINE FORM OF (1S)-1,5-ANHYDRO-1-[3-[[5-(4-FLUOROPHENYL)-2-THIENYL]METHYL]-4-METHYLPHENYL]-D-GLUCITOL JANSSEN PHARMACEUTICA NV (BE) 2018-06-07 — — US disclosed
US-20170333353-A1 BILAYER TABLET FORMULATIONS BRISTOL-MEYERS SQUIBB COMPANY 2017-11-23 — — US disclosed
US-9655852-B2 Tablets containing a 1-(β-D-glucopyranosyl)-3-(phenylthienylmethyl)benzene compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-05-23 — — US disclosed
US-20160228375-A1 TABLETS CONTAINING A 1-(ß-D-GLUCOPYRANOSYL)-3-(PHENYLTHIENYLMETHYL)BENZENE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-08-11 — — US disclosed
US-20160145286-A1 Novel Crystalline Hydrates of 1-(Beta-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl]Benzene LEK PHARMACEUTICALS D.D. (SI) 2016-05-26 — — US disclosed
US-20160108078-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-04-21 — — US disclosed
US-9050258-B2 Bilayer tablet formulations ASTRAZENECA AB (SE) 2015-06-09 — — US disclosed
US-20130034606-A1 IMMEDIATE RELEASE TABLET FORMULATIONS ASTRAZENECA UK LIMITED (GB) 2013-02-07 — — US disclosed
US-20120294936-A1 REDUCED MASS METFORMIN FORMULATIONS ASTRAZENECA UK LIMITED (GB) 2012-11-22 — — US disclosed
US-20120289694-A1 L-PROLINE AND CITRIC ACID CO-CRYSTALS OF (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL JANSSEN PHARMACEUTICA NV (BE) 2012-11-15 — — US disclosed
US-20120282336-A1 BILAYER TABLET FORMULATIONS ASTRAZENECA UK LIMITED (GB) 2012-11-08 — — US disclosed
US-8222219-B2 Glucopyranoside compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-07-17 — — US disclosed
US-20120058941-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-08 — — US disclosed
US-20110212905-A1 CRYSTALLINE FORM OF 1-(BETA-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE HEMIHYDRATE Tanabe Pharma Corporation (JP) 2011-09-01 — — US disclosed
US-7943582-B2 Canagliflozin, a sodium-glucose transporter 2 inhibitor as antiobesity, antidiabetic agent; purity; handling characteristics; easy formulation; storage stability MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-17 — — US disclosed
US-7943788-B2 Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-17 — — US disclosed
US-20080146515-A1 Crystalline form of 1-(beta-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-06-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058941-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 SLC5A2 5/4885SLC5A1 13/4885ABCB11 200/4885
US-20170333353-A1 BILAYER TABLET FORMULATIONS SLC5A2, SLC5A1, GLP1R SLC5A2 1/4885SLC5A1 2/4885ABCB11 315/4885
US-20130034606-A1 IMMEDIATE RELEASE TABLET FORMULATIONS SLC5A2, SLC5A1, SLC2A8 SLC5A2 1/4885SLC5A1 2/4885ABCB11 220/4885
US-20230372375-A1 SGLT-2 INHIBITOR SARCOSINE CO-CRYSTAL, PREPARATION METHOD THEREFOR AND USE THEREOF SLC5A2, SLC5A1, SLC2A2 SLC5A2 1/4885SLC5A1 2/4885ABCB11 340/4885
US-20160228375-A1 TABLETS CONTAINING A 1-(ß-D-GLUCOPYRANOSYL)-3-(PHENYLTHIENYLMETHYL)BENZENE COMPOUND ABCB1, UGGT1, UGT1A1 SLC5A2 22/4885SLC5A1 9/4885ABCB11 20/4885
US-11759474-B2 Use of SGLT-2 inhibitors in the drying-off of non-human mammals SLC5A2, SLC5A1, SLC2A2 SLC5A2 1/4885SLC5A1 2/4885ABCB11 743/4885
US-20120282336-A1 BILAYER TABLET FORMULATIONS SLC5A2, SLC5A1, GLP1R SLC5A2 1/4885SLC5A1 2/4885ABCB11 315/4885
US-20120294936-A1 REDUCED MASS METFORMIN FORMULATIONS GLP1R, SLC5A2, GCKR SLC5A2 2/4885SLC5A1 9/4885ABCB11 738/4885
US-20160108078-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 SLC5A2 5/4885SLC5A1 13/4885ABCB11 200/4885
US-20080146515-A1 Crystalline form of 1-(beta-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate B3GAT3, UGGT1, MGAT3 SLC5A2 305/4885SLC5A1 142/4885ABCB11 4127/4885
US-20110212905-A1 CRYSTALLINE FORM OF 1-(BETA-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE HEMIHYDRATE B3GAT3, UGGT1, MGAT3 SLC5A2 350/4885SLC5A1 154/4885ABCB11 4079/4885
US-20230140631-A1 TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS SLC5A2, SLC5A1, GPR119 SLC5A2 1/4885SLC5A1 2/4885ABCB11 758/4885
US-20120289694-A1 L-PROLINE AND CITRIC ACID CO-CRYSTALS OF (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL CS, PC, FPGS SLC5A2 10/4885SLC5A1 28/4885ABCB11 4286/4885
US-20160145286-A1 Novel Crystalline Hydrates of 1-(Beta-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl]Benzene UGGT1, MGAT2, MGAT1 SLC5A2 6/4885SLC5A1 5/4885ABCB11 68/4885
US-20180155329-A1 ANHYDROUS CRYSTALLINE FORM OF (1S)-1,5-ANHYDRO-1-[3-[[5-(4-FLUOROPHENYL)-2-THIENYL]METHYL]-4-METHYLPHENYL]-D-GLUCITOL SLC5A1, SLC5A2, FBP1 SLC5A2 2/4885SLC5A1 1/4885ABCB11 3175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.